MY ACCOUNT | NEWSLETTER |

Antibiotic-resistant Salmonella and Campylobacter are still high in the EU


Salmonella and Campylobacter bacteria resistant to certain antibiotics that are commonly used in both humans and animals continue to be the main ones detected in the European Union. This is what the European report on antimicrobial resistance in zoonotic and indicator bacteria present in humans, animals, and food shows, corresponding to the period 2018-2019.

The European Center for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA) have published a summary of this report, for the preparation of which have taken into account the data derived from the surveillance of resistance to antimicrobials during the years 2018 and 2019 for Salmonella, Campylobacter, Escherichia coli indicator, and Escherichia coli producing extended spectrum beta-lactamases (ESBL), AmpC beta-lactamases and carbapenemases.

A high percentage of Salmonella

In humans, a high percentage (82.1%) of a type of Salmonella has been reported, such as Kentucky Salmonella resistant to ciprofloxacin, which is an antibiotic that is commonly used to treat certain types of infections. Furthermore, in recent years, it has been reported that the percentage of strains of Salmonella enteritidis resistant to nalidixic acid and / or ciprofloxacin is increasing in certain countries.

The positive news is that between 2015 and 2019, a decrease in the percentage of Salmonella strains resistant to ampicillin and tetracyclines has been observed in humans in eight and eleven EU member states, respectively.

Antimicrobials used to treat some infectious diseases in food animals can be the same or similar to those used for humans.

Antibioresistance appears when microorganisms develop mechanisms that allow them to grow in the presence of antimicrobials, which makes them ineffective for treating infections, which is why the appearance of resistant microorganisms is considered a public health problem.

This report is part of the entire strategy that has been developed in recent years to combat antimicrobial resistance, and both EFSA and ECDC are EU benchmarks.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Prevalence of feline leukemia virus infection and serum antibodies against feline immunodeficiency virus in unowned free-roaming cats

Like0
Dislike0

Additive manufacturing to veterinary practice: Recovery of bony defects after the osteosarcoma resection in canines

Like0
Dislike0

Antimicrobial drug use in poultry

Like0
Dislike0

New hope and compassionate care for animal patients in pain

Like0
Dislike0

Neogen® Renews Official Sponsorship with US Equestrian to Continue Advancing Equine Health Education

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top